Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

3725 - Association of age and body mass index with paclitaxel-induced peripheral neuropathy in patients with breast cancer

Date

10 Oct 2016

Session

Poster display

Presenters

Zohreh Ghoreishi

Citation

Annals of Oncology (2016) 27 (6): 68-99. 10.1093/annonc/mdw365

Authors

Z. Ghoreishi1, A. Esfahani2, S. Keshavarz3

Author affiliations

  • 1 Nutrition Research Center, Tabriz University of Medical Sciences, 5166614711 - Tabriz/IR
  • 2 Hematology And Oncology Research Center, Tabriz University of Medical Sciences, 5166614711 - Tabriz/IR
  • 3 School Of Nutritional Sciences And Dietetics, Tehran University of Medical Sciences, Tehran/IR
More

Resources

Abstract 3725

Background

Peripheral neuropathy is one of the most common dose-limiting side effects of paclitaxel in patients with breast cancer. This study investigated the association of age and body mass index (BMI) with incidence and severity of pacitaxel-induced peripheral neuropathy (PIPN) in these patients.

Methods

Analyzed data belonged to a randomized double-blind placebo controlled trial (ID registrationat ClinicalTrials.gov: NCT01049295) in which the effect of n-3 polyunsaturated fats (PUFAs) on PIPN in patients with breast cancer was examined. Logistic regression analysis (estimation odds ratio) and ordinal regression analysis were used for finding the association of age and BMI with incidence and severity of PIPN (adjusting for intervention effect) respectively.

Results

Age was associated with PIPN in 57 patients with breast cancer (mean age and BMI: 45.97± 10.75 and 45.16± 8.93, respectively) such that for every one-year increase in age, incidence and severity will increase 8% and 7% respectively (OR = 1.08, .95% CI = (1.01 to 1.14), p = 0.015) and B= .07, 0.95% CI = 0.02 to 0.11), p = 0.010, adjusting for intervention effect). Also BMI had a positive association with PIPN, so that a 1 kg/m2 increase in BMI, leads to an increase of incidence and severity by 7% and 8%,respectively(OR = 1.07, .95% CI = (1.00 to 1.15), p = 0.041) and B= .08, 0.95% CI = 0.02 to 0.14), p = 0.012, adjusting for intervention effect).

Conclusions

Older age and higher BMI were associated with greater incidence and severity of PIPN in patients with breast cancer.

Clinical trial identification

ClinicalTrials.gov NCT01049295)

Legal entity responsible for the study

Tehran University of Medical Sciences, Tehran, Iran

Funding

Tehran University of Medical Sciences, Tehran, Iran

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings